EP1912658A4 - Therapeutische protokolle mit hyaluronan - Google Patents

Therapeutische protokolle mit hyaluronan

Info

Publication number
EP1912658A4
EP1912658A4 EP06774784A EP06774784A EP1912658A4 EP 1912658 A4 EP1912658 A4 EP 1912658A4 EP 06774784 A EP06774784 A EP 06774784A EP 06774784 A EP06774784 A EP 06774784A EP 1912658 A4 EP1912658 A4 EP 1912658A4
Authority
EP
European Patent Office
Prior art keywords
hyaluronan
therapeutic protocols
protocols
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06774784A
Other languages
English (en)
French (fr)
Other versions
EP1912658B1 (de
EP1912658A1 (de
Inventor
Tracey Jean Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alchemia Oncology Pty Ltd
Original Assignee
Alchemia Oncology Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alchemia Oncology Pty Ltd filed Critical Alchemia Oncology Pty Ltd
Publication of EP1912658A1 publication Critical patent/EP1912658A1/de
Publication of EP1912658A4 publication Critical patent/EP1912658A4/de
Application granted granted Critical
Publication of EP1912658B1 publication Critical patent/EP1912658B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EP06774784.0A 2005-07-27 2006-07-27 Therapeutische protokolle mit hyaluronan Not-in-force EP1912658B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70314805P 2005-07-27 2005-07-27
PCT/AU2006/001059 WO2007012133A1 (en) 2005-07-27 2006-07-27 Therapeutic protocols using hyaluronan

Publications (3)

Publication Number Publication Date
EP1912658A1 EP1912658A1 (de) 2008-04-23
EP1912658A4 true EP1912658A4 (de) 2012-12-26
EP1912658B1 EP1912658B1 (de) 2017-01-25

Family

ID=37682924

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06774784.0A Not-in-force EP1912658B1 (de) 2005-07-27 2006-07-27 Therapeutische protokolle mit hyaluronan

Country Status (7)

Country Link
US (1) US8937052B2 (de)
EP (1) EP1912658B1 (de)
JP (1) JP5465431B2 (de)
CN (2) CN103784960A (de)
AU (1) AU2006274509B2 (de)
CA (1) CA2616607C (de)
WO (1) WO2007012133A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010113642A (ko) 1999-01-13 2001-12-28 추후기재 약물의 효능을 증대시키기 위한 조성물 및 증대 방법
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US20050042303A1 (en) * 2001-08-27 2005-02-24 Brown Tracey Jean Therapeutic protocols
CN103784960A (zh) 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
CN101287475B (zh) * 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
CN109528763A (zh) * 2018-12-29 2019-03-29 江苏靶标生物医药研究所有限公司 顺铂与透明质酸钠的组合物
CN109512825A (zh) * 2018-12-29 2019-03-26 江苏靶标生物医药研究所有限公司 一种铂类化合物和透明质酸钠的组合物及其应用
CA3133671C (en) * 2019-06-03 2023-12-19 Aihol Corporation Hyaluronan conjugates and uses thereof
US11458204B2 (en) 2020-06-02 2022-10-04 Aihol Corporation Method for improving substitution rate and/or substitution efficiency of hyaluronan-drug conjugates
CA3209512A1 (en) * 2021-02-23 2022-09-01 Edison Oncology Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047561A1 (en) * 1999-12-28 2001-07-05 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA612307A (en) 1961-01-10 International Business Machines Corporation Hydraulic drive tape handling system
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
NO169637C (no) 1983-10-11 1992-07-22 Fidia Spa Fremgangsmaate for fremstilling av terapeutisk aktive hyaluronsyre-fraksjoner
JPS6117A (ja) 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
CA1227427A (en) 1984-08-16 1987-09-29 Albert Landsberger Therapeutic agent for the use in cancer treatment
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US5202431A (en) 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US4665107A (en) * 1986-03-21 1987-05-12 Koh-I-Noor Rapidograph, Inc. Pigment encapsulated latex aqueous colorant dispersions
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5128450A (en) * 1989-06-30 1992-07-07 Urdal David L Nonglycosylated human interleukin-3 analog proteins
DE3931397A1 (de) * 1989-09-20 1991-03-28 Star Gmbh Waelzlager fuer linearbewegungen stichwort: schienenfuehrung mit vorspannungseinstellung
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5095037B1 (en) 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
CA2061703C (en) 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
CA2061566C (en) 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
EP0952855B1 (de) 1991-07-03 2005-07-27 Meditech Research Limited Verwendung von hyaluronan in gentherapie
CA2122519C (en) 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
EP0563475B1 (de) * 1992-03-25 2000-05-31 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
EP0680337A4 (de) 1993-01-12 1997-07-30 Anthony George Gristina Methoden und zusammensetzungen zur direkter konzentrierter verabreichung passiver immunität.
CA2089621A1 (en) 1993-02-16 1994-08-17 Rudolf Edgar Falk Formulations containing hyaluronic acid
US5847002A (en) * 1993-04-16 1998-12-08 Hyal Pharmaceutical Corporation Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
CA2094203A1 (en) 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
AU2479695A (en) 1994-05-09 1995-11-29 Hadasit Medical Research Services & Development Company Ltd Prevention of tumor metastasis
IL114914A0 (en) 1994-08-30 1995-12-08 Hyal Pharma Corp Modulation of cellular activity
IL123383A0 (en) * 1995-09-14 1998-09-24 Bristol Myers Squibb Co Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
KR19990071628A (ko) * 1995-12-01 1999-09-27 하알 팔마큐티칼 코오퍼레이션 약물, 치료요법제 및 다른 글리코자미노글리칸(gags)약량을 표적화시키는 방법
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US5756475A (en) * 1996-01-31 1998-05-26 Nisshin Flour Milling Co., Ltd. Isoprene derivatives
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CA2175282A1 (en) 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
US5756537A (en) * 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
IT1286510B1 (it) 1996-11-29 1998-07-15 Cooperativa Centro Ricerche Po Esteri butirrici ad attivita' antiproliferativa e composizioni farmaceutiche che li contengono
CA2247389C (en) * 1996-12-27 2009-11-24 Seikagaku Corporation Agent for treatment of bladder troubles
ES2189166T3 (es) 1997-04-04 2003-07-01 Fidia Advanced Biopolymers Srl Compuestos del acido hialuronico n-sulfatado, sus derivados y proceso para su preparacion.
CA2208924A1 (en) 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
US20020015724A1 (en) * 1998-08-10 2002-02-07 Chunlin Yang Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
CA2354863A1 (en) 1998-10-02 2000-04-13 University Of Florida Prevention of adhesions
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
KR20010113642A (ko) 1999-01-13 2001-12-28 추후기재 약물의 효능을 증대시키기 위한 조성물 및 증대 방법
PT1044977E (pt) * 1999-03-09 2002-09-30 Sigma Tau Ind Farmaceuti Derivados de camptotecina com actividade antitumoral
IT1306643B1 (it) 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
SE9904121D0 (sv) 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US6749865B2 (en) * 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US6620927B2 (en) 2001-02-22 2003-09-16 Anika Therapeutics, Inc. Thiol-modified hyaluronan
CA2445985A1 (en) 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells
US20050042303A1 (en) * 2001-08-27 2005-02-24 Brown Tracey Jean Therapeutic protocols
EP1480656A4 (de) * 2002-02-15 2007-07-18 Res Dev Foundation Hyaluronsäure-vermittelte adenovirus-transduktion
JP2004262777A (ja) * 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
US7183381B2 (en) * 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
CN103784960A (zh) 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
CN101287475B (zh) 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047561A1 (en) * 1999-12-28 2001-07-05 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROWN TRACEY J ET AL: "An investigation of the use of hyaluronic acid as a targeted transport vehicle for irinotecan in the treatment of metastatic colorectal cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, April 2005 (2005-04-01), & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005, pages 328, XP008158176, ISSN: 0197-016X *
BROWN TRACEY J ET AL: "The development of hyaluronic acid as a targeted transport vehicle for chemotherapeutic drugs.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, April 2005 (2005-04-01), & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005, pages 332, XP008158187, ISSN: 0197-016X *
BROWN TRACEY J ET AL: "The effect of hyaluronic acid on the activity of intra-tumoral and intestinal beta-glucuronidases - a potential mechanism for increasing the therapeutic index of irinotecan.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 47, April 2006 (2006-04-01), & 97TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); WASHINGTON, DC, USA; APRIL 01 -05, 2006, pages 724 - 725, XP008158175, ISSN: 0197-016X *
ROGERTHEDODGER: "HyCAMP(TM) CLINICAL TRIAL - EARLY POSITIVE RESULTS - ADDITIONAL PATIENTS TO BE RECRUITED", 20 April 2004 (2004-04-20), XP055044770, Retrieved from the Internet <URL:http://boards.fool.co.uk/hycamp-clinical-trial-8498094.aspx> [retrieved on 20121119] *
See also references of WO2007012133A1 *

Also Published As

Publication number Publication date
AU2006274509B2 (en) 2012-01-19
JP5465431B2 (ja) 2014-04-09
AU2006274509A1 (en) 2007-02-01
JP2009502813A (ja) 2009-01-29
CA2616607C (en) 2015-06-02
US20090054537A1 (en) 2009-02-26
WO2007012133A1 (en) 2007-02-01
CN101287474A (zh) 2008-10-15
EP1912658B1 (de) 2017-01-25
EP1912658A1 (de) 2008-04-23
US8937052B2 (en) 2015-01-20
CN101287474B (zh) 2014-08-20
CA2616607A1 (en) 2007-02-01
CN103784960A (zh) 2014-05-14

Similar Documents

Publication Publication Date Title
HK1205935A1 (en) Non-lithotripsic kidney-stone therapy
EP1912658A4 (de) Therapeutische protokolle mit hyaluronan
GB0509613D0 (en) Fixator
IL185917A0 (en) Immunogenic molecules
GB0509326D0 (en) Therapeutic compounds
GB0509573D0 (en) Therapeutic compounds
GB0518361D0 (en) Therapeutic compounds
GB0509405D0 (en) Therapeutic compounds
GB0524103D0 (en) Healing
GB0504206D0 (en) Combination therapy
GB0513747D0 (en) Therapeutic compounds
GB0509052D0 (en) Combination therapy
GB0516068D0 (en) Well treatment
ZA200709627B (en) Combination therapy
GB0525540D0 (en) New treatment
GB0507003D0 (en) Therapeutic
GB0511769D0 (en) Treatment
GB0518235D0 (en) Therapeutic compounds
GB0518720D0 (en) Therapeutic combination
GB0501655D0 (en) Therapeutic use
GB2427141B (en) Fixator
GB0502171D0 (en) Well treatment
GB0515580D0 (en) Therapeutic compounds
GB0522538D0 (en) Massagers
GB0526121D0 (en) Combination therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20121127

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/70 20060101ALI20121121BHEP

Ipc: A61K 45/06 20060101ALI20121121BHEP

Ipc: A61P 35/00 20060101ALI20121121BHEP

Ipc: A61K 31/728 20060101AFI20121121BHEP

Ipc: A61P 1/00 20060101ALI20121121BHEP

17Q First examination report despatched

Effective date: 20130828

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALCHEMIA ONCOLOGY PTY LIMITED

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160406

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20161214

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 863724

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006051637

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170125

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 863724

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170525

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170426

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170425

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170525

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006051637

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20171026

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006051637

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170727

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180201

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170727

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125